Open AccessRituximab (Rituxan) Therapy for Severe Thyroid-Associated Ophthalmopathy Diminishes IGF-1R+ T Cells
Author(s) -
Allison N. McCoy,
Denise S. Kim,
Erin F. Gillespie,
Stephen Atkins,
Terry J. Smith,
Raymond S. Douglas
Publication year - 2014
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2013-3207
Subject(s) - rituximab , medicine , cd20 , cd8 , gastroenterology , flow cytometry , thyroid , endocrinology , immunology , lymphoma , immune system
Rituximab depletes CD20(+) B cells and has shown potential benefit in thyroid-associated ophthalmopathy (TAO). The impact of rituximab on T cell phenotype in TAO is unexplored.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom